At a glance
- Originator Kuraray
- Class Antineoplastics; Furans; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Mar 2004 Discontinued for Cancer in Japan (unspecified route)
- 26 May 2001 Profile reviewed but no significant changes made
- 16 Oct 1996 No-Development-Reported for Cancer in Japan (Unknown route)